Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa

American Journal of Clinical Pathology

Volumn 136, Issue 6, 2011, Pages 881-888

  Gunia, Sven ^a   Koch, Stefan ^a   Hakenberg, Oliver W ^b   May, Matthias ^c   Kakies, Christoph ^b   Erbersdobler, Andreas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c St Elisabeth Clinic Straubing   (Germany)

Author keywords

Flat lesions of urinary bladder mucosa; HER2 expression profiles; Histologic differential diagnosis; Immunohistochemistry

Indexed keywords

CYTOKERATIN 20; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER MUCOSA; BREAST CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UROTHELIAL CARCINOMA IN SITU; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 82655171627     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPKUZ69LXZGFEA     Document Type: Article

References (29)

1. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25:356-362. (Pubitemid 32174205)
2. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. Am J Surg Pathol. 2001;25:1074-1078.
3. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469-2474. (Pubitemid 29244858)
4. Wolf H, Melsen F, Pedersen SE, et al. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl. 1994;157:147-151. (Pubitemid 24205663)
5. Rouprêt M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update [published online ahead of print January 14, 2011]. Eur Urol. 2011;59:584-594. doi:10.1016/j.eururo.2010.12.042.
6. Babjuk M, Oosterlinck W, Sylvester E, et al. Guidelines on non-muscle invasive bladder cancer. Arnhem, the Netherlands: European Association of Urology; 2010.
7. Shariat SF, Palapattu GS, Karakiewitz PI, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007;51:152-160. (Pubitemid 44821530)
8. Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008;53:1138-1148.
9. Williamson SR, Montironi R, Lopez-Beltran A, et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol. 2010;76:112-126.
10. Yin M, Bastacky S, Parwani AV, et al. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol. 2008;39:527-535.
11. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol. 2010;41:155-162.
12. Brandau S, Böhle A. Bladder cancer, I: molecular and genetic basis of carcinogenesis. Eur Urol. 2001;39:491-497. (Pubitemid 32678962)
13. Laé M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21:815-819.
14. Hansel DE, Swain E, Dreicer R, et al. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol. 2008;130:274-281.
15. Kolla SB, Seth A, Singh MK, et al. Prognostic significance of HER2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol. 2008;40:321-327.
16. Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004;40:56-63. (Pubitemid 37542318)
17. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61:818-824. (Pubitemid 351969725)
18. Kay E, O'Grady A, Morgan JM, et al. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol. 2004;57:1140-1144. (Pubitemid 39486517)
19. Eble JN, Sauter G, Epstein JI, et al., eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
20. Montironi R, Cheng L, Lopez-Beltran A, et al. Inverted (endophytic) noninvasive lesions and neoplasms of the urothelium: the Cinderella group has yet to be fully exploited. Eur Urol. 2011;59:225-230.
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
22. Kline MJ, Wilkinson EJ, Askeland R, et al. DNA tetraploidy in Feulgen-stained bladder washings assessed by image cytometry. Anal Quant Cytol Histol. 1995;17:129-134.
23. Wojcik EM, Brownlie RJ, Bassler TJ, et al. Superficial urothelial (umbrella) cells: a potential cause of abnormal DNA ploidy results in urine specimens. Anal Quant Cytol Histol. 2000;22:411-415.
24. Schwarz S, Rechenmacher M, Filbeck T, et al. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. J Clin Pathol. 2008;61:272-277. (Pubitemid 351354228)
25. Ohta JI, Miyoshi Y, Uemura H, et al. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res. 2001;7:2463-2467. (Pubitemid 32751650)
26. Tetu B, Fradet Y, Allard P, et al. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996;155:1784-1788. (Pubitemid 26127001)
27. Massard C, Albouy B, Gross-Goupil M, et al. Bladder cancer and new drugs [in French]. Bull Cancer. 2010;97(suppl Cancer de la vessie):43-50.
28. Hauser-Kronberger C, Peham K, Grall J, et al. Novel approach of human epidermal growth factor receptor detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol. 2006;175:875-880. (Pubitemid 43200000)
29. Parwani AV, Levi AW, Epstein JI, et al. Urinary bladder biopsy with denuded mucosa: denuding cystitiscytopathologic correlates. Diagn Cytopathol. 2004;30:297-300. (Pubitemid 38579817)